An investigation on behalf of investors in POZEN Inc. (NASDAQ:POZN) shares over potential wrongdoing at POZEN was announced and NASDAQ:POZN stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/06/2015 -- An investigation on behalf of current long-term investors in shares of POZEN Inc. (NASDAQ:POZN) shares was announced over potential breaches of fiduciary duties by certain officers and directors at POZEN.
Investors who purchased shares of POZEN Inc. (NASDAQ:POZN) and currently hold any of those NASDAQ:POZN shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain POZEN officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
POZEN Inc. reported that its annual Total Revenue rose from $5.35 million in 2012 to $10.32 million in 2013 while its respective Net Loss increased from $25.28 million to $16.71 million. Shares of POZEN Inc. (NASDAQ:POZN) grew from $2.51 per share in November 2011 to as high as $9.77 per share in late 2013.
On April 28, 2014 POZEN Inc. announced that "their drug candidates PA8140/PA32540 (aspirin and omeprazole) delayed release tablets have received a complete response letter from the U.S. Food and Drug Administration" ("FDA").
On December 17, 2014, POZEN Inc announced that its investigational drug candidates YOSPRALA 81/40 and 325/40 received a second complete response letter from the FDA. In this complete response letter, the FDA used identical wording to that of the first complete response letter. Shares of POZEN Inc. (NASDAQ:POZN) declined to as low as $7.62 per share on December 17, 2014.
On January 2, 2015, NASDAQ:POZN shares closed at 7.88 per share.
Those who purchased shares of POZEN Inc. (NASDAQ:POZN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego